Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down from $41. The firm views Denali as “a key beneficiary” in an evolving landscape following FDA recognition of elevated heparan sulfate as a surrogate endpoint and models $359M in unadjusted sales for Tividenofusp Alfa in Hunter disease and $646M in unadjusted sales for DNL126 for Sanfilippo disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks
- Denali Therapeutics Discontinues DNL343 ALS Trial
- Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
- Denali Therapeutics price target lowered to $35 from $38 at B. Riley
- Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer